Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) Sees Large Decrease in Short Interest

Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT – Get Free Report) saw a large decline in short interest in the month of October. As of October 30th, there was short interest totaling 6,660 shares, a decline of 46.0% from the October 15th total of 12,328 shares. Based on an average daily volume of 28,516 shares, the days-to-cover ratio is currently 0.2 days. Currently, 0.1% of the company’s stock are short sold.

Regentis Biomaterials Price Performance

RGNT traded up $0.03 during midday trading on Tuesday, hitting $1.22. 13,013 shares of the company’s stock traded hands, compared to its average volume of 47,162. The stock’s fifty day simple moving average is $1.59 and its 200-day simple moving average is $2.62. Regentis Biomaterials has a one year low of $1.14 and a one year high of $15.50.

Regentis Biomaterials (NYSEAMERICAN:RGNT – Get Free Report) last released its earnings results on Friday, September 11th. The company reported ($0.22) earnings per share for the quarter.

About Regentis Biomaterials

(Get Free Report)

Regentis Biomaterials is a medical technology company developing biomaterials for the repair of damaged cartilage. Its lead product, GelrinC, is an implant designed to treat focal cartilage defects in the knee. The cell-free hydrogel is placed in the defect and is intended to support the formation of repair tissue as the material gradually degrades. The company’s work focuses on providing an off-the-shelf alternative to cartilage-repair procedures that require harvesting a patient’s cells or tissue.

Further Reading

Receive News & Ratings for Regentis Biomaterials Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regentis Biomaterials and related companies with MarketBeat.com's FREE daily email newsletter.